Journal of Viral Hepatitis

Preactivation of the interferon signalling in liver is correlated with nonresponse to interferon alpha therapy in patients chronically infected with hepatitis B virus
pp. e1-e10(10)
Authors: Xiao, C.; Qin, B.; Chen, L.; Liu, H.; Zhu, Y.; Lu, X.

The tumour necrosis factor-α-238A allele increases the risk of chronic HBV infection in European populations
pp. e11-e17(7)
Authors: Zheng, M.-H.; Xiao, D.-D.; Lin, X.-F.; Wu, S.-J.; Peng, M.-M.; Yu, X.-Y.; Liu, W.-Y.; Li, L.-F.; Shi, K.-Q.; Fan, Y.-C.; Chen, Y.-P.

Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers
pp. e18-e25(8)
Authors: Zou, H.; Chen, Y.; Duan, Z.; Zhang, H.; Pan, C.

Hepatitis B virus suppresses the functional interaction between natural killer cells and plasmacytoid dendritic cells
pp. e26-e33(8)
Authors: Shi, C. C.; Tjwa, E. T. T. L.; Biesta, P. J.; Boonstra, A.; Xie, Q.; Janssen, H. L. A.; Woltman, A. M.

Comparison of the hepatitis B virus core, surface and polymerase gene substitution rates in chronically infected patients
pp. e34-e40(7)
Authors: van de Klundert, M. A. A.; Cremer, J.; Kootstra, N. A.; Boot, H. J.; Zaaijer, H. L.

Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B
pp. e41-e47(7)
Authors: Kwon, J. H.; Jang, J. W.; Lee, S.; Lee, J.; Chung, K. W.; Lee, Y. S.; Choi, J. Y.

Impact of hepatitis B virus infection on metabolic profiles and modifying factors
pp. e48-e57(10)
Authors: Hsu, C.-S.; Liu, C.-H.; Wang, C.-C.; Tseng, T.-C.; Liu, C.-J.; Chen, C.-L.; Chen, P.-J.; Chen, D.-S.; Kao, J.-H.

Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection
pp. e58-e65(8)
Authors: Waidmann, O.; Bihrer, V.; Pleli, T.; Farnik, H.; Berger, A.; Zeuzem, S.; Kronenberger, B.; Piiper, A.

Tumour necrosis factor-α-857T allele reduces the risk of hepatitis B virus infection in an Asian population
pp. e66-e72(7)
Authors: Shi, K.-Q.; Cai, X.-H.; Xiao, D.-D.; Wu, S.-J.; Peng, M.-M.; Lin, X.-F.; Liu, W.-Y.; Fan, Y.-C.; Chen, Y.-P.; Zheng, M.-H.

Inhibition of IκB kinase by thalidomide increases hepatitis C virus RNA replication
pp. e73-e80(8)
Authors: Rance, E.; Tanner, J. E.; Alfieri, C.

Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity
pp. e81-e88(8)
Authors: Bachmetov, L.; Gal-Tanamy, M.; Shapira, A.; Vorobeychik, M.; Giterman-Galam, T.; Sathiyamoorthy, P.; Golan-Goldhirsh, A.; Benhar, I.; Tur-Kaspa, R.; Zemel, R.

Cerebral microglial activation in patients with hepatitis c: <i>in vivo</i> evidence of neuroinflammation
pp. e89-e96(8)
Authors: Grover, V. P. B.; Pavese, N.; Koh, S.-B.; Wylezinska, M.; Saxby, B. K.; Gerhard, A.; Forton, D. M.; Brooks, D. J.; Thomas, H. C.; Taylor-Robinson, S. D.

Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up
pp. e97-e104(8)
Authors: Maruoka, D.; Imazeki, F.; Arai, M.; Kanda, T.; Fujiwara, K.; Yokosuka, O.

Prospective study of risk factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients
pp. e105-e111(7)
Authors: Ho, E. Y.; Ha, N. B.; Ahmed, A.; Ayoub, W.; Daugherty, T.; Garcia, G.; Cooper, A.; Keeffe, E. B.; Nguyen, M. H.

Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection
pp. e112-e119(8)
Authors: Yamada, I.; Suzuki, F.; Kamiya, N.; Aoki, K.; Sakurai, Y.; Kano, M.; Matsui, H.; Kumada, H.

Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response
pp. e120-e125(6)
Authors: Craxi, A.; Koutsounas, S.; Ogurtsov, P.; Chemello, L.; Maticic, M.; Torras, J.; Diago, M.; Tartaglione, M. T.; Witthoeft, T.; Yu, X.; Faruqi, R.; Chaudhri, E.; Pedicone, L. D.; Zuckerman, E.

Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection
pp. e126-e133(8)
Authors: Miki, D.; Ohishi, W.; Ochi, H.; Hayes, C. N.; Abe, H.; Tsuge, M.; Imamura, M.; Kamatani, N.; Nakamura, Y.; Chayama, K.

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C
pp. e134-e142(9)
Authors: Hayashi, N.; Okanoue, T.; Tsubouchi, H.; Toyota, J.; Chayama, K.; Kumada, H.

Fibrosis progression under maintenance interferon in hepatitis C is better detected by blood test than liver morphometry
pp. e143-e153(11)
Authors: Calès, P.; Zarski, J. P.; Marc Chapplain, J.; Bertrais, S.; Sturm, N.; Michelet, C.; Babany, G.; Chaigneau, J.; Eddine Charaf, M.; multicentric groups Fibrosys ANRS HC 12 Fibrostopcr10,

Hepatic expression of MxA and OAS1 in an <i>ex vivo</i> liver slice assay independently predicts treatment outcomes in chronic hepatitis C
pp. e154-e162(9)
Authors: Cheng, J.-C.; Yeh, Y.-J.; Huang, Y.-H.; Liang, K.-H.; Chang, M.-L.; Lin, C.-Y.; Yeh, C.-T.

Examining hepatitis c virus testing practices in primary care clinics
pp. e163-e169(7)
Authors: Almario, C. V.; Vega, M.; Trooskin, S. B.; Navarro, V. J.

Hepatic iron overload is common in chronic hepatitis B and is more severe in patients coinfected with hepatitis D virus
pp. e170-e176(7)
Authors: Sebastiani, G.; Tempesta, D.; Alberti, A.

Immunohistochemistry for the diagnosis of hepatitis E virus infection
pp. e177-e183(7)
Authors: Gupta, P.; Jagya, N.; Pabhu, S. B.; Durgapal, H.; Acharya, S. K.; Panda, S. K.

Transient elastography for predicting clinical outcomes in patients with chronic liver disease
pp. e184-e193(10)
Authors: Klibansky, D. A.; Mehta, S. H.; Curry, M.; Nasser, I.; Challies, T.; Afdhal, N. H.

Predictors of outcome in children with acute viral hepatitis and coagulopathy
pp. e194-e201(8)
Authors: Srivastava, A.; Yachha, S. K.; Poddar, U.

The association of HIV viral load with indirect markers of liver injury
pp. e202-e211(10)
Authors: Forrester, J. E.; Rhee, M. S.; McGovern, B. H.; Sterling, R. K.; Knox, T. A.; Terrin, N.

Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis
pp. e212-e219(8)
Authors: Friedrich-Rust, M.; Nierhoff, J.; Lupsor, M.; Sporea, I.; Fierbinteanu-Braticevici, C.; Strobel, D.; Takahashi, H.; Yoneda, M.; Suda, T.; Zeuzem, S.; Herrmann, E.

Ischaemic colitis during interferon treatment for chronic hepatitis C: report of two cases and literature review
pp. e220-e224(5)
Authors: Kawaguchi, T.; Ide, T.; Itou, M.; Suetsugu, M.; Yoshioka, S.; Sakata, M.; Taniguchi, E.; Oriishi, T.; Sumie, S.; Tsuruta, O.; Sata, M.

Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C
pp. 77-87(11)
Authors: Stickel, F.; Helbling, B.; Heim, M.; Geier, A.; Hirschi, C.; Terziroli, B.; Wehr, K.; De Gottardi, A.; Negro, F.; Gerlach, T.

Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis
pp. 88-93(6)
Authors: Alavian, S.-M.; Tabatabaei, S. V.; Behnava, B.

Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin
pp. 94-102(9)
Authors: Reau, N.; Hamzeh, F. M.; Lentz, E.; Zhou, X.; Jensen, D.

Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus
pp. 103-111(9)
Authors: Pham, T. N. Q.; Coffin, C. S.; Churchill, N. D.; Urbanski, S. J.; Lee, S. S.; Michalak, T. I.

Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection
pp. 112-119(8)
Authors: Jafferbhoy, H.; Miller, M.H.; Dunbar, J.K.; Tait, J.; Mcleod, S.; Dillon, J.F.

Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b
pp. 120-127(8)
Authors: Vermehren, J.; Susser, S.; Lange, C. M.; Forestier, N.; Karey, U.; Hughes, E.; Ralston, R.; Tong, X.; Zeuzem, S.; Sarrazin, C.

CCL5 mRNA is a marker for early fibrosis in chronic hepatitis C and is regulated by interferon-α therapy and toll-like receptor 3 signalling
pp. 128-137(10)
Authors: Katsounas, A.; Trippler, M.; Wang, B.; Polis, M.; Lempicki, R. A.; Kottilil, S.; Gerken, G.; Schlaak, J. F.

Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion
pp. 138-146(9)
Authors: Chen, Y.-C.; Huang, S.-F.; Chu, C.-M.; Liaw, Y.-F.

Characterizing hepatitis B stigma in Chinese immigrants
pp. 147-152(6)
Authors: Cotler, S. J.; Cotler, S.; Xie, H.; Luc, B. J.; Layden, T. J.; Wong, S. S.